UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 573

Sortiert nach

Accelerating progress from advanced to early breast Cancer

Breast (Edinburgh), 2021-04, Vol.56, p.S4

Rugo, H.

2021

Volltextzugriff (PDF)

Immunotherapy toxicity: identification and management

Breast cancer research and treatment, 2022-02, Vol.192 (1), p.1-17

2022

Volltextzugriff (PDF)

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

Annals of oncology, 2014-12, Vol.25 (12), p.2357-2362

2014

Volltextzugriff (PDF)

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Breast cancer research and treatment, 2019-04, Vol.174 (3), p.719-729

2019

Volltextzugriff (PDF)

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Annals of oncology, 2019-03, Vol.30 (3), p.397-404

2019

Volltextzugriff (PDF)

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

Annals of oncology, 2019-03, Vol.30 (3), p.405-411

2019

Volltextzugriff (PDF)

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

Annals of oncology, 2021-02, Vol.32 (2), p.208-217

2021

Volltextzugriff (PDF)

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

Annals of oncology, 2021-12, Vol.32 (12), p.1475-1495

2021

Volltextzugriff (PDF)

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

Annals of oncology, 2021-08, Vol.32 (8), p.983-993

2021

Volltextzugriff (PDF)

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Annals of oncology, 2020-11, Vol.31 (11), p.1526-1535

2020

Volltextzugriff (PDF)

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

Annals of oncology, 2020-12, Vol.31 (12), p.1623-1649

2020

Volltextzugriff (PDF)

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial

Annals of oncology, 2022-04, Vol.33 (4), p.384-394

2022

Volltextzugriff (PDF)

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

Annals of oncology, 2018-04, Vol.29 (4), p.888-894

2018

Volltextzugriff (PDF)

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Annals of oncology, 2021-09, Vol.32 (9), p.1148-1156

2021

Volltextzugriff (PDF)

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

Annals of oncology, 2014-07, Vol.25 (7), p.1328-1333

2014

Volltextzugriff (PDF)

Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

Annals of oncology, 2020-08, Vol.31 (8), p.1001-1010

2020

Volltextzugriff (PDF)

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

Annals of oncology, 2014-04, Vol.25 (4), p.808-815

2014

Volltextzugriff (PDF)

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

Annals of oncology, 2018-09, Vol.29 (9), p.1939-1947

2018

Volltextzugriff (PDF)

Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer

Annals of oncology, 2020-05, Vol.31 (5), p.582-589

2020

Volltextzugriff (PDF)

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study

Annals of oncology, 2022-06, Vol.33 (6), p.616-627

2022

Volltextzugriff (PDF)

The breast cancer continuum in hormone-receptor–positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors

Annals of oncology, 2008-01, Vol.19 (1), p.16-27

Rugo, H. S.

2008

Volltextzugriff (PDF)

The efficacy, challenges, and facilitators of telemedicine in post-treatment cancer survivorship care: an overview of systematic reviews

Annals of oncology, 2021-12, Vol.32 (12), p.1552-1570

2021

Volltextzugriff (PDF)

Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer

ESMO open, 2022-08, Vol.7 (4), p.100553-100553, Article 100553

2022

Volltextzugriff (PDF)

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Annals of oncology, 2017-01, Vol.28 (1), p.16-33

2017

Volltextzugriff (PDF)

Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy

Annals of oncology, 2016-03, Vol.27 (3), p.519-525

2016

Volltextzugriff (PDF)

1 – 25 von 573

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieClinical Cancer Research

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(569)
Mit Volltextzugriff
(550)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(136)
Life Sciences & Biomedicine
(133)
Humans
(128)
Oncology
(109)
Female
(91)
Middle Aged
(64)
Adult
(58)
Breast Cancer
(58)
Breast Neoplasms - Drug Therapy
(47)
Aged
(44)
Biological And Medical Sciences
(41)
Medical Sciences
(39)
Tumors
(36)
Breast Neoplasms - Pathology
(35)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(31)
Male
(26)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(24)
Chemotherapy
(23)
Hematology, Oncology And Palliative Medicine
(22)
Antineoplastic Agents
(21)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Accelerating progress from advanced to early breast Cancer

Immunotherapy toxicity: identification and management

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study

The breast cancer continuum in hormone-receptor–positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors

The efficacy, challenges, and facilitators of telemedicine in post-treatment cancer survivorship care: an overview of systematic reviews

Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy

Aktive Filter

Suchergebnisse filtern